Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease

Biochemical and Biophysical Research Communications

Volumn 399, Issue 4, 2010, Pages 716-720

  Togawa, Tadayasu ^a   Kawashima, Ikuo ^a,b   Kodama, Takashi ^a   Tsukimura, Takahiro ^a   Suzuki, Toshihiro ^a   Fukushige, Tomoko ^c   Kanekura, Takuro ^c   Sakuraba, Hitoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Galactosidase A; Biomarker; Enzyme replacement therapy; Fabry disease; Globotriaosylceramide; Globotriaosylsphingosine

Indexed keywords

AGALSIDASE BETA; BIOLOGICAL MARKER; GLOBOTRIAOSYLCERAMIDE; GLOBOTRIAOSYLSPHINGOSINE; UNCLASSIFIED DRUG; ALPHA GALACTOSIDASE; GLOBOTRIAOSYL LYSOSPHINGOLIPID; GLYCOLIPID; RECOMBINANT PROTEIN; SPHINGOLIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; ENZYME REPLACEMENT; FABRY DISEASE; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY PARENCHYMA; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN; TISSUE LEVEL; TREATMENT RESPONSE; ANIMAL; BLOOD; DRUG EFFECTS; KIDNEY; PATHOLOGY; PROGNOSIS;

ALPHA-GALACTOSIDASE; ANIMALS; BIOLOGICAL MARKERS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GLYCOLIPIDS; KIDNEY; MICE; PROGNOSIS; RECOMBINANT PROTEINS; SPHINGOLIPIDS;

MUS;

EID: 77956264231     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.006     Document Type: Article

References (23)

1. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3733-3774. McGraw-Hill Inc., New York. eighth ed. C.R. Scriver, W.A. Sly, A.L. Beaudet, D. Valle (Eds.).
2. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001, 68:711-722.
3. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 2001, 345:9-16.
4. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., Anderson T., Gillespie F., Oliver K.L., Jeffries N.O., Doo E., Liang T.J., Kreps C., Gunter K., Frei K., Crutchfield K., Selden R.F., Brady R.O. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 2000, 97:365-370.
5. Schaefer R.M., Tylki-Szymańska A., Hilz M.J. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 2009, 69:2179-2205.
6. Mehta A., Beck M., Elliot P., Giugliani R., Linhart A., Sunder-Plassmann G., Schiffmann R., Barbey F., Ries M., Clarke J.T.R. Fabry outcome survey investigators, Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009, 374:1986-1996.
7. Fervenza F.C., Torra R., Warnock D.G. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics 2008, 2:823-843.
8. Thurberg B.L., Fallon J.T., Mitchell R., Aretz T., Gordon R.E., O'Callaghan M.W. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009, 119:2561-2567.
9. Salviati A., Burlina A.P., Borsini W. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement therapy, and support therapy. Neurol. Sci. 2010, 31:299-306.
10. Kitagawa T., Ishige N., Suzuki K., Owada M., Ohashi T., Kobayashi M., Eto Y., Tanaka A., Mills K., Winchester B., Keutzer J. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol. Genet. Metab. 2005, 85:196-202.
11. Whitfield P.D., Calvin J., Hogg S., O'Driscoll E., Halsall D., Burling K., Maguire G., Wright N., Cox T.M., Meikle P.J., Deegan P.B. Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 2005, 28:21-33.
12. Rozenfeld P.A., De Francesco N.P., Borrajo G.J., Ceci R., Fossati C.A. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Clin. Chim. Acta 2009, 403:194-197.
13. Young E., Mills K., Morris P., Vellodi A., Lee P., Waldek S., Winchester B. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Pediatr. 2005, 94:51-54.
14. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopmann W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA 2008, 105:2812-2817.
15. Togawa T., Kodama T., Suzuki T., Sugawara K., Tsukimura T., Ohashi T., Ishige N., Suzuki K., Kitagawa T., Sakuraba H. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol. Genet. Metab. 2010, 100:257-261.
16. M.D. Sanchez-Niño, A.B. Sanz, S. Carrasco, M.A. Saleem, P.W. Mathieson, J.M. Valdivielso, M. Ruiz-Ortega, J. Egido, A. Ortiz, Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy, Nephrol. Dial. Transplant. 2010 May 26. [Epub ahead of print].
17. Ohshima T., Murray G.J., Swaim W.D., Longenecker G., Quirk J.M., Cardarelli C.O., Sugimoto Y., Pastan I., Gottesman M.M., Brady R.O., Kulkarni A.B. α-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA 1997, 94:2540-2544.
18. Ohshima T., Schiffmann R., Murray G.J., Kopp J., Quirk J.M., Stahl S., Chan C.-C., Zerfas P., Tao-Cheng J.-H., Ward J.M., Brady R.O., Kulkarni A.B. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. USA 1999, 96:6423-6427.
19. Kawashima I., Takeuchi I., Ohsawa M., Kotani M., Tajima Y., Inomata T., Izumi T., Sakuraba H. Phospholipid storage in myocardium of a unique Japanese case of idiopathic cardiomyopathy. Clin. Chim. Acta 2007, 378:142-146.
20. Kotani M., Kawashima I., Ozawa H., Ogura K., Ariga T., Tai T. Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine. Arch. Biochem. Biophys. 1994, 310:89-96.
21. Tajima Y., Kawashima I., Tsukimura T., Sugawara K., Kuroda M., Suzuki T., Togawa T., Chiba Y., Jigami Y., Ohno K., Fukushige T., Kanekura T., Itoh K., Ohashi T., Sakuraba H. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 2009, 85:569-580.
22. Hwu W.L., Chien Y.H., Lee N.C., Chiang S.C., Dobrovolny R., Huang A.C., Yeh H.Y., Chao M.C., Lin S.J., Kitagawa T., Desnick R.J., Hsu L.W. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum. Mutat. 2009, 30:1397-1405.
23. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., Desnick R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 2006, 79:31-40.